Dr. Reddy's Laboratories enters into voluntary licensing agreement with Lilly

12 May 2021 Evaluate

Dr. Reddy's Laboratories has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for the manufacture and commercialization of the drug, baricitinib, in India. The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1172.25 -3.30 (-0.28%)
19-Jan-2026 12:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.00
Dr. Reddys Lab 1172.25
Cipla 1390.75
Zydus Lifesciences 865.00
Lupin 2187.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×